Psilocybin-assisted psychotherapy can produce profound, sustained relief from anxiety and depression in people with terminal illness, rather than brief mood softening. One to two guided doses of about 20–30 mg generated large effect sizes (Cohen’s d ~0.8–1.3) and lifted quality-of-life and meaning-in-life scores by roughly 30–60%, with benefits lasting for months. Participants also showed marked increases in emotional openness and acceptance of death, indicating that psychedelic therapy can restore psychological well-being and a sense of connection at life’s end, not just blunt distress.